Menu Search
Equities

Caplin Point Laboratories Ltd

CAPLIPOINT:NSI

Caplin Point Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,963.75
  • Today's Change17.75 / 0.91%
  • Shares traded60.78k
  • 1 Year change+59.09%
  • Beta0.6620
Data delayed at least 15 minutes, as of Nov 22 2024 09:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in INR

The 2 analysts offering 12 month price targets for Caplin Point Laboratories Ltd have a median target of 2,340.00, with a high estimate of 2,400.00 and a low estimate of 2,280.00. The median estimate represents a 19.08% increase from the last price of 1,965.00.
High22.1%2,400.00
Med19.1%2,340.00
Low16.0%2,280.00

Dividends in INR

In 2024, Caplin Point Laboratories Ltd reported a dividend of 5.00 INR, which represents a 11.11% increase over last year. The 2 analysts covering the company expect dividends of 3.40 INR for the upcoming fiscal year, a decrease of 32.00%.
Div growth (TTM)11.11%
More ▼

Earnings history & estimates in INR

Caplin Point Laboratories Ltd reported annual 2024 earnings of 59.90 per share on May 16, 2024.
Average growth rate+20.83%
More ▼

Revenue history & estimates in INR

Caplin Point Laboratories Limited had 2nd quarter 2025 revenues of 4.83bn. This bettered the 4.72bn estimate of the one analyst covering the company. This was 22.20% above the prior year's 2nd quarter results.
Average growth rate+4.20%
Caplin Point Laboratories Limited had revenues for the full year 2024 of 16.94bn. This was 15.50% above the prior year's results.
Average growth rate+18.40%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.